Copyright
©The Author(s) 2017.
World J Gastroenterol. May 28, 2017; 23(20): 3721-3729
Published online May 28, 2017. doi: 10.3748/wjg.v23.i20.3721
Published online May 28, 2017. doi: 10.3748/wjg.v23.i20.3721
Table 5 Evaluation of gastric cancer patient survival by proliferating cell nuclear antigen and E-cadherin
| Indicators | Survival time <3 yr | Survival time >3 yr | Sensitivity | Specificity | Accuracy |
| PCNA | 93.33% | 38.89% | 0.64 | ||
| Positive | 28 | 22 | |||
| Negative | 2 | 14 | |||
| E-cadherin | 80.0% | 41.67% | 0.59 | ||
| Positive | 6 | 15 | |||
| Negative | 24 | 21 | |||
| The combination of both (PCNA[+] and E-cadherin[-]) | 80.0% | 66.67% | 0.73 | ||
| Positive | 24 | 12 | |||
| Negative | 6 | 24 |
- Citation: Hu L, Li HL, Li WF, Chen JM, Yang JT, Gu JJ, Xin L. Clinical significance of expression of proliferating cell nuclear antigen and E-cadherin in gastric carcinoma. World J Gastroenterol 2017; 23(20): 3721-3729
- URL: https://www.wjgnet.com/1007-9327/full/v23/i20/3721.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i20.3721